[go: up one dir, main page]

WO1996039504A3 - Procede permettant la distinction entre cancers metastatiques et cancers non metastatiques, et polynucleotides et polypeptides utilises dans ce procede - Google Patents

Procede permettant la distinction entre cancers metastatiques et cancers non metastatiques, et polynucleotides et polypeptides utilises dans ce procede Download PDF

Info

Publication number
WO1996039504A3
WO1996039504A3 PCT/EP1996/002461 EP9602461W WO9639504A3 WO 1996039504 A3 WO1996039504 A3 WO 1996039504A3 EP 9602461 W EP9602461 W EP 9602461W WO 9639504 A3 WO9639504 A3 WO 9639504A3
Authority
WO
WIPO (PCT)
Prior art keywords
metastatic
methods
polynucleotides
polypeptides
distinguishing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP1996/002461
Other languages
English (en)
Other versions
WO1996039504A2 (fr
Inventor
Emilay Shtivelman
Adam Sampson-Johannes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Pharma GmbH Austria
Sandoz AG
Systemix Inc
Original Assignee
Sandoz Erfindungen Verwaltungs GmbH
Sandoz AG
Systemix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz Erfindungen Verwaltungs GmbH, Sandoz AG, Systemix Inc filed Critical Sandoz Erfindungen Verwaltungs GmbH
Priority to AU63008/96A priority Critical patent/AU6300896A/en
Publication of WO1996039504A2 publication Critical patent/WO1996039504A2/fr
Publication of WO1996039504A3 publication Critical patent/WO1996039504A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Cette invention concerne des séquences nucléotidiques codant un nouvel ADN complémentaire classique spécifique du carcinome à petites cellules du poumon, la séquence d'acides aminés de la protéine correspondante, des procédés permettant l'expression et la purification de cette protéine, des anticorps dirigés contre cette protéine ainsi que leurs procédés d'utilisation.
PCT/EP1996/002461 1995-06-06 1996-06-06 Procede permettant la distinction entre cancers metastatiques et cancers non metastatiques, et polynucleotides et polypeptides utilises dans ce procede Ceased WO1996039504A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU63008/96A AU6300896A (en) 1995-06-06 1996-06-06 Methods for distinguishing metastatic and non-metastatic cancers, polynucleotides and polypeptides for use therein

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47172395A 1995-06-06 1995-06-06
US08/471,723 1995-06-06

Publications (2)

Publication Number Publication Date
WO1996039504A2 WO1996039504A2 (fr) 1996-12-12
WO1996039504A3 true WO1996039504A3 (fr) 1997-01-09

Family

ID=23872750

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1996/002461 Ceased WO1996039504A2 (fr) 1995-06-06 1996-06-06 Procede permettant la distinction entre cancers metastatiques et cancers non metastatiques, et polynucleotides et polypeptides utilises dans ce procede

Country Status (2)

Country Link
AU (1) AU6300896A (fr)
WO (1) WO1996039504A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4263599A (en) * 1998-05-18 1999-12-06 Isis Innovation Limited Nucleic acid encoding protein, down-regulated in metastasis (drim), and its diagnostic and therapeutic use
WO2005007692A1 (fr) * 2003-07-11 2005-01-27 Uab Research Foundation Anticorps qui reconnaissent la proteine brms1 et leurs utilisations

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992000757A1 (fr) * 1990-07-09 1992-01-23 Research Corporation Technologies, Inc. Diagnostic du cancer metastatique a l'aide du gene mts-1
WO1994001777A1 (fr) * 1992-07-14 1994-01-20 Michigan Cancer Foundation Procede pour determiner le potentiel metastatique de cellules tumorales
WO1994020147A1 (fr) * 1993-03-04 1994-09-15 Systemix, Inc. Modele de metastase chez de petits animaux

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992000757A1 (fr) * 1990-07-09 1992-01-23 Research Corporation Technologies, Inc. Diagnostic du cancer metastatique a l'aide du gene mts-1
WO1994001777A1 (fr) * 1992-07-14 1994-01-20 Michigan Cancer Foundation Procede pour determiner le potentiel metastatique de cellules tumorales
WO1994020147A1 (fr) * 1993-03-04 1994-09-15 Systemix, Inc. Modele de metastase chez de petits animaux

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
8TH INTERNATIONAL CONGRESS OF IMMUNOLOGY, Budapest, Hungary, August 23-28, 1992 Springer-Verlag Budapest See M.SALMI ET AL.: Expression of domain 3 *
EMBL DATABASE, Accession number T72319 Sequence reference HS31940 from human cDNA clone 85879;17 March 1995 *
EMBL DATABASE, Accession number T96211 Sequence reference HS21168 from human cDNA clone 120965;14 April 1995 *
POLLOCK ET AL.: "Cloning, sequencing, and expression of the gene encoding the high-molecular-weight Cytochrome c from Desulfovibrio vulgaris Hildenborough", JOURNAL OF BACTERIOLOGY, vol. 173, no. 1, January 1991 (1991-01-01), pages 220 - 228, XP000609018 *
S.SEITER ET AL.: "Prevention of tumor metastasis formation by anti-variant CD44", JOURNAL OF EXPERIMENTAL MEDICINE, vol. 177, no. 2, 1 February 1993 (1993-02-01), NEW YORK US, pages 443 - 455, XP002018001 *

Also Published As

Publication number Publication date
WO1996039504A2 (fr) 1996-12-12
AU6300896A (en) 1996-12-24

Similar Documents

Publication Publication Date Title
AU7165287A (en) DNA encoding streptavidin, streptavidin produced therefrom, fused polypeptides which include amino acid sequences present in streptavidin and uses thereof
CA2263889A1 (fr) Proteines ligands de p-selectine
SI0917571T1 (en) Agouti-related gene
WO2000008057A3 (fr) Molecules designees b7l-1
HU9601448D0 (en) Novel apoptosis-modulating proteins, dna encoding the proteins and methods of use thereof
IL193886A0 (en) Antibodies that bind to ldcam sequences
WO2000006738A3 (fr) Acides nucleiques et proteines de streptococcus pneumoniae
WO1998021343A8 (fr) Genes codant des proteines de telomerase
HUT46061A (en) Dna sequences encoding hirudin-like protein and process for producing such proteins
WO1993018146A3 (fr) Proteines formant des complexes avec des chaperones et leurs ligands, leurs fragments, leur obtention et leurs applications biologiques
CA2302147A1 (fr) Procedes d'analyse de proteines
CA2336261A1 (fr) Genes et proteines cycline e2
WO1995030001A3 (fr) Nouvelle proteine ligand de p-selectine
EP1117779A4 (fr) PROTEINE $i(MORAXELLA CATARRHALIS), SEQUENCE D'ACIDE NUCLEIQUE ET UTILISATIONS DE CELLES-CI
HUP0300851A3 (en) Purified proteins, recombinant dna sequences and processes for producing caffeine free beverages
AU1239997A (en) Polypeptides corresponding to the amino acid sequences of proteins p57 or p9.5 of Borna disease virus, nucleic acid fragments coding therefore and their use for diagnostic and immunization purposes
WO1996039504A3 (fr) Procede permettant la distinction entre cancers metastatiques et cancers non metastatiques, et polynucleotides et polypeptides utilises dans ce procede
NZ294019A (en) Proteins associated with the hippocampus; dna sequences coding therefor, antibodies to the proteins
WO2000020450A3 (fr) Gene alpha-2/delta
EP0970192A4 (fr) ACIDE NUCLEIQUE CODANT UNE PROTEINE ALGU $i(M. TUBERCULOSIS)
EP0816498A3 (fr) Récepteur pour acide aminé excitateur et acides nucléiques liés
WO2001087932A3 (fr) Sept protéines transmembranaires et polynucléotides les codant
CA2311646A1 (fr) Gene tsa305
WO2001049714A3 (fr) Polypeptides nope, acides nucleiques les codant, et modes d'utilisation
DE69939587D1 (en) Semaphorin polypeptide

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA